Development and Validation of RP HPLC method for the estimation of Etoricoxib in bulk and tablets.

Authors

  • Hiral Satishchandra Mehta Department of Quality Assurance, Shree Devi College of Pharmacy, Airport Road, Mangalore (Karnataka)
  • Menezes Cylma Department of Quality Assurance, Shree Devi College of Pharmacy, Airport Road, Mangalore (Karnataka)
  • Akhilesh Dubey Department of Quality Assurance, Shree Devi College of Pharmacy, Airport Road, Mangalore (Karnataka)
  • Reema Narayan Department of Quality Assurance, Shree Devi College of Pharmacy, Airport Road, Mangalore (Karnataka)

DOI:

https://doi.org/10.7439/ijapa.v3i2.49

Abstract

Objective: Objective of the present analytical research work was to develop and validate Reverse Phase High Performance Liquid Chromatographic method (RP-HPLC Method) for the Etoricoxib in bulk and tablets dosage form. Methods: A RP-HPLC method has been developed and validated for estimation of ETOR in pharmaceutical oral dosage form. Method A (RP-HPLC Method): The RP-HPLC Method for Etoricoxib was developed using Shimadzu HPLC, LC-10, temperature maintained 25 0C, phenorex Gemini C18 (250 mm 4.60 mm 5?m), as stationary particle, isocratic mode. Water: ACN: OPA: TEA (40:60:0.1:0.1, v/vv/v). Mobile phase was maintained at a flow rate of 1.0 ml/min and detection was carried out at 245 nm. Results: Etoricoxib was found to be linear in the concentration range of 8 - 12 ?g/ml for RP-HPLC method. Retention time was found to be 2.7 min for Etoricoxib. The amount of Etoricoxib in marketed formulation was found to be 99.14 %. Interpretation and Conclusion: Results of assay and validation study were found to be satisfactory. So, the method can be successfully applied for the routine analysis of Etoricoxib.

Downloads

Download data is not yet available.

Downloads

Published

2013-07-21

Issue

Vol. 3 No. 2 (2013): Apr-Jun

Section

Research Articles

License

Authors who publish with this journal agree to the following terms:

a) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.

b)Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.

c) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

After acceptance of the article, the author has to submit copyright form signed by all authors.

How to Cite

1.
Development and Validation of RP HPLC method for the estimation of Etoricoxib in bulk and tablets. Int J of Adv in Phar Ana [Internet]. 2013 Jul. 21 [cited 2025 Mar. 15];3(2):51-5. Available from: https://ssjournals.co.in/index.php/ijapa/article/view/1370
Crossref
Scopus
Google Scholar
Europe PMC